Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price ...

Buy APLS near 28.9 target 36.47 stop loss @ 28.82 Details The technical summary data tells us to buy APLS near 28.9 with an ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This ...

Wells Fargo analyst Derek Archila has maintained their neutral stance on APLS stock, giving a Hold rating yesterday. Derek Archila has given his Hold rating due to a combination of factors ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...

Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics ...

Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s rating is based on Apellis Pharmaceuticals’ strategic ...

Check the time stamp on this data. Updated AI-Generated Signals for Apellis Pharmaceuticals Inc. (APLS) available here: APLS.